Aquestive Therapeutics says studies show DBF successfully administered

Aquestive Therapeutics announced findings from two clinical studies, including the Adult Epilepsy Monitoring Unit study, showing that its investigational diazepam buccal film, or DBF, was successfully used and had similar bioavailability whether administered between seizures or during or shortly after seizures in adults with poorly controlled tonic-clonic seizures or focal seizures with impaired awareness. The findings are detailed in two presentations at the annual meeting of the American Epilepsy Society. “Currently, the only formulations of diazepam approved by the U.S. Food and Drug Administration for acute treatment of seizures are injected or rectally administered, which can be cumbersome and uncomfortable for patients who suffer from repetitive seizures. These findings, showing consistent usability and bioavailability, demonstrate Libervant’s potential to address patient needs for an orally administered treatment alternative that is efficacious, easy to use and portable anywhere. We are excited to add this to our growing epilepsy franchise,” said Keith Kendall, CEO of Aquestive Therapeutics.

https://thefly.com/landingPageNews.php?id=2831355